Multiple sclerosis therapy enters phase 2

| Print |  Email
Articles - January 2013
Monday, December 10, 2012

 

BY LINDA BAKER

0113 GamePlan ArtielleMultiple sclerosis is an immune disorder in which the body mistakenly attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord. The resulting neurological symptoms can range from numbness and tingling to paralysis. Although existing therapies reduce inflammation caused by MS, researchers have long sought to develop a therapy that will actually repair the neurological damage.

Enter Artielle ImmunoTherapeutics, a Portland biotech company that will launch an FDA phase-two clinical trial this year for a new therapy researchers say appears to also reverse the dysregulation of the immune system associated with MS and promotes nerve regeneration. The company takes its name from a phonetic rendering of its proprietary technology — recombinant T-cell receptor ligands.

“There is recovery from the disease,” says Arthur Vandenbark, a founding Artielle scientist and a neurology researcher affiliated with the Portland VA Medical Center and Oregon Health & Science University. “That’s what’s so exciting.” The phase-two trial is considered a critical milestone, as it will show the drug can work in MS patients — and not just in animal models. A phase-one trial, indicating the drug’s safety, was completed a few years ago. According to OHSU’s tech-transfer office, Artielle represents the first OHSU drug discovery to be commercialized this far in the clinical trial process by a company that was formed and has remained in Oregon.

Oregon can be a tough environment for homegrown biotech companies, which often struggle to locate investment capital. Founded eight years ago, Artielle is one of the success stories. It has raised $25 million of venture capital, including $2 million from Northwest Technology Ventures and Reference Capital Management, both located in Portland, and $11 million from Sanderling Ventures in the Bay Area, where Artielle CEO Peter McWilliams is based.

The phase-two trial is funded by the Department of Veterans Affairs and will help Artielle achieve its next financial goal: a buyout or partnership with a pharmaceutical company to help bring the product to market.

Only one in about 5,000 biotech startups develops a commercial drug, but the Artielle team thinks they have a shot. The market is saturated with purely anti-inflammatory drugs, says McWilliams. But Artielle’s technology goes further. “This is a disease-modifying agent,” he says.

 

Comments   

 
Guest
0 #1 new ms drugGuest 2013-01-09 19:02:09
what is the main component of the up coming new drug
Quote | Report to administrator
 
 
Guest
-1 #2 infoGuest 2013-02-09 20:49:44
This article gives some info:

http://www.msdiscovery.org/research-resources/drug-pipeline/499-rtl1000

Melanie J
Quote | Report to administrator
 

More Articles

The Carbon Calculus

February 2015
Friday, January 23, 2015
BY KIM MOORE | OB RESEARCH EDITOR

Carbon pricing is gaining momentum in Oregon, sparking concern for energy-intensive businesses — but also opportunity to expand a homespun green economy.


Read more...

Which Way to Chinatown?

February 2015
Monday, January 26, 2015
BY AMY MILSHTEIN | PHOTOS BY JASON E. KAPLAN

The Jade International District, already Portland's center of Asian life, is poised for rejuvenation. Where does that leave the westside's historic Chinatown?


Read more...

Uncertainty about convention center hotel could cost Portland an NBA All-Star Game

The Latest
Wednesday, February 18, 2015
463545460BY JACOB PALMER | OB DIGITAL NEWS EDITOR

NBA commissioner: "I would love to end up having an All-Star Game in Portland. It's really just a function of ensuring that we can fit in town."


Read more...

10 quotes explaining crisis at Port of Portland

The Latest
Friday, February 20, 2015
022015 port portland OBM-thumbBY JACOB PALMER | OB DIGITAL NEWS EDITOR

The ongoing labor disputes at the Port of Portland came to a head two weeks ago when Hanjin, the container port's largest client, notified its customers it would be ending its direct route to Oregon.


Read more...

Light Moves

February 2015
Monday, January 26, 2015
BY JACOB PALMER

Fittingly, Light at Play — a business whose sole purpose is to create mesmerizing ambience — was conceived at Burning Man.


Read more...

Transportation Fairness Alliance holds demonstration in Pioneer Square

The Latest
Wednesday, January 14, 2015
IMG 3367BY JACOB PALMER | OB DIGITAL NEWS EDITOR

Portland's cab companies urged city hall for consideration as officials weigh new rules for Uber and other ridesharing companies.


Read more...

Where do Portland demographics rank among the largest 50 cities in the US?

The Latest
Tuesday, February 10, 2015
thumbpdxinperspectiveBY JACOB PALMER | OB DIGITAL NEWS EDITOR

The Portland in Perspective study, done by the City Budget Office, was released Tuesday.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS